February 19, 2026 · Form 4 insider transaction
Galletta Christopher bought 35,000 shares of Trevi Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
This option was granted on February 19, 2026. The 35,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.